{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:28:57Z","timestamp":1790882937554,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite being the second most common neurodegenerative disorder, little is known about Parkinson\u2019s disease (PD) pathogenesis. A number of genetic factors predispose towards PD, among them mutations in\n                    <jats:italic>GBA1<\/jats:italic>\n                    , which encodes the lysosomal enzyme acid-\u03b2-glucosidase. We now perform non-targeted, mass spectrometry based quantitative proteomics on five brain regions from PD patients with a\n                    <jats:italic>GBA1<\/jats:italic>\n                    mutation (PD-GBA) and compare to age- and sex-matched idiopathic PD patients (IPD) and controls. Two proteins were differentially-expressed in all five brain regions whereas significant differences were detected between the brain regions, with changes consistent with loss of dopaminergic signaling in the substantia nigra, and activation of a number of pathways in the cingulate gyrus, including ceramide synthesis. Mitochondrial oxidative phosphorylation was inactivated in PD samples in most brain regions and to a larger extent in PD-GBA. This study provides a comprehensive large-scale proteomics dataset for the study of PD-GBA.\n                  <\/jats:p>","DOI":"10.1038\/s41531-024-00645-x","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:02:32Z","timestamp":1707350552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Large-scale proteomics analysis of five brain regions from Parkinson\u2019s disease patients with a GBA1 mutation"],"prefix":"10.1038","volume":"10","author":[{"given":"Shani","family":"Blumenreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Nehushtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meital","family":"Kupervaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2651-1591","authenticated-orcid":false,"given":"Tali","family":"Shalit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gabashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammar","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2990-0243","authenticated-orcid":false,"given":"Ivan","family":"Milenkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0013-0115","authenticated-orcid":false,"given":"Anthony H.","family":"Futerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"645_CR1","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.ncl.2016.06.012","volume":"34","author":"A Lee","year":"2016","unstructured":"Lee, A. & Gilbert, R. M. Epidemiology of Parkinson Disease. Neurol. Clin. 34, 955\u2013965 (2016).","journal-title":"Neurol. Clin."},{"key":"645_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino, R. & Schapira, A. H. V. Parkinson disease. Eur. J. Neurol. 27, 27\u201342 (2020).","journal-title":"Eur. J. Neurol."},{"key":"645_CR3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson\u2019s Disease. N. Engl. J. Med. 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med."},{"key":"645_CR4","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1365-2141.2004.05351.x","volume":"129","author":"M Jmoudiak","year":"2005","unstructured":"Jmoudiak, M. & Futerman, A. H. Gaucher disease: Pathological mechanisms and modern management. Br. J. Haematol. 129, 178\u2013188 (2005).","journal-title":"Br. J. Haematol."},{"key":"645_CR5","doi-asserted-by":"crossref","unstructured":"Futerman, A. H. & Hardy, J. Finding common ground. Nature 537, S160\u2013S161 (2016).","DOI":"10.1038\/537S160a"},{"key":"645_CR6","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awx285","volume":"140","author":"LA Robak","year":"2017","unstructured":"Robak, L. A. et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease. Brain 140, 3191\u20133203 (2017).","journal-title":"Brain"},{"key":"645_CR7","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/mds.23774","volume":"26","author":"T Shachar","year":"2011","unstructured":"Shachar, T. et al. Lysosomal storage disorders and Parkinson\u2019s disease: Gaucher disease and beyond. Mov. Disord. 26, 1593\u20131604 (2011).","journal-title":"Mov. Disord."},{"key":"645_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21144966","volume":"21","author":"S Blumenreich","year":"2020","unstructured":"Blumenreich, S., Barav, O. B., Jenkins, B. J. & Futerman, A. H. Lysosomal storage disorders shed light on lysosomal dysfunction in Parkinson\u2019s disease. Int. J. Mol. Sci. 21, 1\u201312 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"645_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3390\/genes12101545","volume":"12","author":"T Usenko","year":"2021","unstructured":"Usenko, T. et al. Comparative transcriptome analysis in monocyte-derived macrophages of asymptomatic gba mutation carriers and patients with gba-associated parkinson\u2019s disease. Genes (Basel). 12, 1545 (2021).","journal-title":"Genes (Basel)."},{"key":"645_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-022-00554-8","volume":"17","author":"GM Riboldi","year":"2022","unstructured":"Riboldi, G. M. et al. Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson\u2019s disease. Mol. Neurodegener. 17, 1\u201317 (2022).","journal-title":"Mol. Neurodegener."},{"key":"645_CR11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/brain\/awab371","volume":"145","author":"C Galvagnion","year":"2022","unstructured":"Galvagnion, C. et al. Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote \u03b1-synuclein aggregation. Brain 145, 1038\u20131051 (2022).","journal-title":"Brain"},{"key":"645_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/mds.26278","volume":"30","author":"ME Gegg","year":"2015","unstructured":"Gegg, M. E. et al. No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov. Disord. 30, 1085\u20131089 (2015).","journal-title":"Mov. Disord."},{"key":"645_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41531-022-00363-2","volume":"8","author":"S Blumenreich","year":"2022","unstructured":"Blumenreich, S. et al. Elevation of gangliosides in four brain regions from Parkinson\u2019s disease patients with a GBA mutation. npj Park. Dis. 8, 99 (2022).","journal-title":"npj Park. Dis."},{"key":"645_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s10571-019-00700-9","volume":"39","author":"A Dixit","year":"2019","unstructured":"Dixit, A., Mehta, R. & Singh, A. K. Proteomics in Human Parkinson\u2019s Disease: Present Scenario and Future Directions. Cell. Mol. Neurobiol. 39, 901\u2013915 (2019).","journal-title":"Cell. Mol. Neurobiol."},{"key":"645_CR15","doi-asserted-by":"crossref","unstructured":"Ferrer, I. Proteomics and lipidomics in the human brain. in Handbook of Clinical Neurology 150 285\u2013302 (Elsevier B.V., 2018).","DOI":"10.1016\/B978-0-444-63639-3.00020-7"},{"key":"645_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"645_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2018.00419","volume":"9","author":"LJ de Schipper","year":"2018","unstructured":"de Schipper, L. J. et al. Altered whole-brain and network-based functional connectivity in Parkinson\u2019s disease. Front. Neurol. 9, 1\u201310 (2018).","journal-title":"Front. Neurol."},{"key":"645_CR18","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/mds.28232","volume":"35","author":"S Blumenreich","year":"2020","unstructured":"Blumenreich, S., Jenkins, B. J., Barav, O. B., Milenkovic, I. & Futerman, A. H. The Lysosome and Nonmotor Symptoms: Linking Parkinson\u2019s Disease and Lysosomal Storage Disorders. Mov. Disord. 35, 2150\u20132155 (2020).","journal-title":"Mov. Disord."},{"key":"645_CR19","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1242\/jcs.146365","volume":"129","author":"G Napolitano","year":"2016","unstructured":"Napolitano, G. & Ballabio, A. TFEB at a glance. J. Cell Sci. 129, 2475\u20132481 (2016).","journal-title":"J. Cell Sci."},{"key":"645_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1083\/jcb.201802032","volume":"218","author":"L Qiang","year":"2019","unstructured":"Qiang, L. et al. Pancreatic tumor cell metastasis is restricted by MT1-MMP binding protein MTCBP-1. J. Cell Biol. 218, 317\u2013332 (2019).","journal-title":"J. Cell Biol."},{"key":"645_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0120194","volume":"10","author":"H Zigdon","year":"2015","unstructured":"Zigdon, H. et al. Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease. PLoS One 10, 1\u201311 (2015).","journal-title":"PLoS One"},{"key":"645_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/jnr.490330402","volume":"33","author":"GVW Johnson","year":"1992","unstructured":"Johnson, G. V. W. & Jope, R. S. The role of microtubule\u2010associated protein 2 (MAP\u20102) in neuronal growth, plasticity, and degeneration. J. Neurosci. Res. 33, 505\u2013512 (1992).","journal-title":"J. Neurosci. Res."},{"key":"645_CR23","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.parkreldis.2015.04.028","volume":"21","author":"N Kresojevi\u0107","year":"2015","unstructured":"Kresojevi\u0107, N. et al. Presenting symptoms of GBA-related Parkinson\u2019s disease. Park. Relat. Disord. 21, 804\u2013807 (2015).","journal-title":"Park. Relat. Disord."},{"key":"645_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mds.26071","volume":"30","author":"K Brockmann","year":"2015","unstructured":"Brockmann, K. et al. GBA-associated Parkinson\u2019s disease: Reduced survival and more rapid progression in a prospective longitudinal study. Mov. Disord. 30, 407\u2013411 (2015).","journal-title":"Mov. Disord."},{"key":"645_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2018.00138","volume":"9","author":"T Prell","year":"2018","unstructured":"Prell, T. Structural and functional brain patterns of non-motor syndromes in Parkinson\u2019s disease. Front. Neurol. 9, 1\u20139 (2018).","journal-title":"Front. Neurol."},{"key":"645_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1371\/journal.pone.0066910","volume":"8","author":"A Poisson","year":"2013","unstructured":"Poisson, A. et al. A Functional Magnetic Resonance Imaging Study of Pathophysiological Changes Responsible for Mirror Movements in Parkinson\u2019s Disease. PLoS One 8, 6\u201311 (2013).","journal-title":"PLoS One"},{"key":"645_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/hmg\/ddq454","volume":"20","author":"S Lesage","year":"2011","unstructured":"Lesage, S. et al. Large-scale screening of the Gaucher\u2019s disease-related glucocerebrosidase gene in Europeans with Parkinson\u2019s disease. Hum. Mol. Genet. 20, 202\u2013210 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"645_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neurobiolaging.2018.02.028","volume":"67","author":"PJ Hallett","year":"2018","unstructured":"Hallett, P. J. et al. Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. Neurobiol. Aging 67, 189\u2013200 (2018).","journal-title":"Neurobiol. Aging"},{"key":"645_CR29","doi-asserted-by":"publisher","first-page":"43452","DOI":"10.1074\/jbc.M307104200","volume":"278","author":"C Riebeling","year":"2003","unstructured":"Riebeling, C., Allegood, J. C., Wang, E., Merrill, A. H. & Futerman, A. H. Two Mammalian Longevity Assurance Gene (LAG1) Family Members, trh1 and trh4, Regulate Dihydroceramide Synthesis Using Different Fatty Acyl-CoA Donors. J. Biol. Chem. 278, 43452\u201343459 (2003).","journal-title":"J. Biol. Chem."},{"key":"645_CR30","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.1074\/jbc.M707386200","volume":"283","author":"EL Laviad","year":"2008","unstructured":"Laviad, E. L. et al. Characterization of ceramide synthase 2: Tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J. Biol. Chem. 283, 5677\u20135684 (2008).","journal-title":"J. Biol. Chem."},{"key":"645_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1212\/WNL.0000000000000004","volume":"82","author":"RM Wu","year":"2014","unstructured":"Wu, R. M., Lin, C. H. & Lin, H. I. The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 82, 283 (2014).","journal-title":"Neurology"},{"key":"645_CR32","doi-asserted-by":"crossref","unstructured":"Thomas, R., Hallett, P. J. & Isacson, O. Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson\u2019s disease genetic risk. International Review of Neurobiology 154 (Elsevier Inc., 2020).","DOI":"10.1016\/bs.irn.2020.02.004"},{"key":"645_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-69480-3","volume":"10","author":"R Raghunathan","year":"2020","unstructured":"Raghunathan, R., Hogan, J. D., Labadorf, A., Myers, R. H. & Zaia, J. A glycomics and proteomics study of aging and Parkinson\u2019s disease in human brain. Sci. Rep. 10, 1\u20139 (2020).","journal-title":"Sci. Rep."},{"key":"645_CR34","doi-asserted-by":"crossref","unstructured":"Winchester, L. et al. Identification of a novel proteomic Biomarker in Parkinson\u2019s Disease: Discovery and Replication in Blood, brain and CSF. medRxiv 2021.12.26.21268282 (2021).","DOI":"10.1101\/2021.12.26.21268282"},{"key":"645_CR35","doi-asserted-by":"publisher","first-page":"eabm6393","DOI":"10.1126\/sciadv.abm6393","volume":"8","author":"SH Kuo","year":"2022","unstructured":"Kuo, S. H. et al. Mutant glucocerebrosidase impairs \u03b1-synuclein degradation by blockade of chaperone-mediated autophagy. Sci. Adv. 8, eabm6393 (2022).","journal-title":"Sci. Adv."},{"key":"645_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/mc.22264","volume":"55","author":"J Pratt","year":"2016","unstructured":"Pratt, J., Iddir, M., Bourgault, S. & Annabi, B. Evidence of MTCBP-1 interaction with the cytoplasmic domain of MT1-MMP: Implications in the autophagy cell index of high-grade glioblastoma. Mol. Carcinog. 55, 148\u2013160 (2016).","journal-title":"Mol. Carcinog."},{"key":"645_CR37","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1074\/jbc.M114.603431","volume":"290","author":"T Nishihara","year":"2015","unstructured":"Nishihara, T. et al. Matrix metalloproteinase-14 both sheds cell surface neuronal glial antigen 2 (NG2) proteoglycan on macrophages and governs the response to peripheral nerve injury. J. Biol. Chem. 290, 3693\u20133707 (2015).","journal-title":"J. Biol. Chem."},{"key":"645_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/iub.319","volume":"62","author":"M Levy","year":"2010","unstructured":"Levy, M. & Futerman, A. H. Mammalian ceramide synthases. IUBMB Life 62, 347\u2013356 (2010).","journal-title":"IUBMB Life"},{"key":"645_CR39","doi-asserted-by":"crossref","unstructured":"Ben-david, O. et al. Encephalopathy Caused by Ablation of Very Long Acyl Chain Ceramide Synthesis May Be Largely Due to Reduced Galactosylceramide Levels * \u25a1. 286, 30022\u201330033 (2011).","DOI":"10.1074\/jbc.M111.261206"},{"key":"645_CR40","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367\u20131372 (2008).","journal-title":"Nat. Biotechnol."},{"key":"645_CR41","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"645_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00401-012-0964-x","volume":"124","author":"GG Kovacs","year":"2012","unstructured":"Kovacs, G. G. et al. An antibody with high reactivity for disease-associated \u03b1-synuclein reveals extensive brain pathology. Acta Neuropathol. 124, 37\u201350 (2012).","journal-title":"Acta Neuropathol."},{"key":"645_CR43","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/hmg\/ddt468","volume":"23","author":"T Farfel-Becker","year":"2014","unstructured":"Farfel-Becker, T. et al. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic gaucher disease leads to neurodegeneration. Hum. Mol. Genet. 23, 843\u2013854 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"645_CR44","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1074\/jbc.M112.414714","volume":"288","author":"HG K\u00f6rschen","year":"2013","unstructured":"K\u00f6rschen, H. G. et al. The non-lysosomal \u03b2-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi. J. Biol. Chem. 288, 3381\u20133393 (2013).","journal-title":"J. Biol. Chem."},{"key":"645_CR45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1042\/bj3030377","volume":"303","author":"I Meivar-Levy","year":"1994","unstructured":"Meivar-Levy, I., Horowitz, M. & Futerman, A. H. Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D-erythro-glucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease. Biochem. J. 303, 377\u2013382 (1994).","journal-title":"Biochem. J."},{"key":"645_CR46","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1139\/y59-099","volume":"37","author":"EG Bligh","year":"1959","unstructured":"Bligh, E. G. & Dyer, W. J. A Rapid Method Of Total Lipid Extraction And Purification. Can. J. Biochem. Physiol. 37, 911\u2013917 (1959).","journal-title":"Can. J. Biochem. Physiol."},{"key":"645_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1194\/jlr.D052001","volume":"56","author":"R Tidhar","year":"2015","unstructured":"Tidhar, R., Sims, K., Rosenfeld-Gur, E., Shaw, W. & Futerman, A. H. A rapid ceramide synthase activity using NBD-sphinganine and solid phase extraction. J. Lipid Res. 56, 193\u2013199 (2015).","journal-title":"J. Lipid Res."},{"key":"645_CR48","doi-asserted-by":"publisher","first-page":"21025","DOI":"10.1074\/jbc.M112.363580","volume":"287","author":"EL Laviad","year":"2012","unstructured":"Laviad, E. L., Kellys, S., Merrill, A. H. & Futerman, A. H. Modulation of ceramide synthase activity via dimerization. J. Biol. Chem. 287, 21025\u201321033 (2012).","journal-title":"J. Biol. Chem."},{"key":"645_CR49","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.nbd.2014.05.020","volume":"69","author":"GG Kovacs","year":"2014","unstructured":"Kovacs, G. G. et al. Intracellular processing of disease-associated \u03b1-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiol. Dis. 69, 76\u201392 (2014).","journal-title":"Neurobiol. Dis."},{"key":"645_CR50","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bcmd.2005.07.005","volume":"35","author":"E Beutler","year":"2005","unstructured":"Beutler, E., Gelbart, T. & Scott, C. R. Hematologically important mutations: Gaucher disease. Blood Cells, Mol. Dis. 35, 355\u2013364 (2005).","journal-title":"Blood Cells, Mol. Dis."},{"key":"645_CR51","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1021\/acschembio.7b00276","volume":"12","author":"F Ben Bdira","year":"2017","unstructured":"Ben Bdira, F. et al. Stabilization of Glucocerebrosidase by Active Site Occupancy. ACS Chem. Biol. 12, 1830\u20131841 (2017).","journal-title":"ACS Chem. Biol."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00645-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00645-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00645-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T15:30:00Z","timestamp":1731252600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00645-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1038\/s41531-024-00645-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3028475\/v1","asserted-by":"object"}]},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"6 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}